Recently Featured

NICE Recommends MSD’s Pembrolizumab for Locally Advanced Cervical Cancer

July 8, 2026
The National Institute for Health and Care Excellence (NICE) has recommended the use of MSD’s pembrolizumab as a treatment option for locally advanced cervical cancer (LACC) in England. This decision marks a significant milestone as pembrolizumab becomes the first immunotherapy approved for this indication, providing new hope for women facing this challenging diagnosis. The approval…

MHRA Innovation Office Offers Comprehensive Guidance and Support for Pharma Professionals

July 8, 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the availability of its Innovation Office, which provides tailored guidance and support to pharmaceutical professionals navigating the complexities of regulatory requirements. This initiative aims to enhance the collaboration between the MHRA and industry stakeholders, ensuring that innovative medicines and healthcare products meet the necessary standards…

BIO 2026: Indiana, biopharma investment and the Lilly effect

July 8, 2026
Indiana is positioning itself as a burgeoning hub for biopharma investment, driven significantly by the influence of Eli Lilly and Company. As the state prepares for the BIO 2026 conference, local leaders, including BioCrossroads’ Vince Wong, are actively strategizing to showcase Indiana’s unique advantages in the biopharmaceutical sector. The Lilly effect, characterized by substantial investment…

Ionis scores transformational FDA label expansion for Tryngolza

July 8, 2026
Ionis Pharmaceuticals has achieved a significant milestone with the FDA’s approval of an expanded label for Tryngolza, marking it as the first treatment specifically sanctioned for severe hypertriglyceridemia. This pivotal decision not only validates the therapeutic potential of antisense oligonucleotide technology but also positions Tryngolza as a critical player in a niche yet impactful market.…

Ongoing Cases